Open Access Medical Books



Edited by Manuela Fiuza .

194 pages .
Open Access .

Many drugs, including those used in cancer patient treatments can cause injuries to human heart. As number of cured cancer patients continues to increase, the issue of cardiotoxicity is currently being subject of intensive research, since it can harmly influence long-term health condition of patients. This book reviews this subject over seven chapters which are briefly described below.
In Chapter 1 the authors address the issue of cardiac damage caused by natural toxins.
This compressive review focuses on toxins affecting heart physiology through modulation of the ionic channels in plasma membrane, describing most of the toxins affecting heart function, their targets in the heart tissue, mode of action and the most important clinical effects of envenomation.
Chapter 2 revisits the issue of nitric acid as a protective mechanism involved in the recovery of myocardial ischaemia. The results of this study clearly show the action of NO in isoproterenol-induced myocardial infarction and suggest the importance to assess the role of NO in pre infarction and early post infarction stages in patients. It is possible that the therapeutic modulation of NO release might prevent the cytotoxic actions of the excessive NO release which facilitate the recovery of the patient at the post infarction stage.
Chapter 3 reviews in depth the problem of cardiotoxicity of cancer therapy. The authors review different most used drugs and their potential mechanisms responsible for cardiac injury and major cardiac manifestations. Authors also revised the issue of cardiac involvement in patients undergoing mediastinal radiotherapy.
Chapter 4 addresses the issue of Neureregulin1-Erb signaling in Doxorubicin-induced cardiotoxicity. In this chapter authors review several studies, from basic and clinical findings regarding the potential cardioprotective role of neureregulin in prevention and promising therapeutic approach to prevent or reverse myocardial dysfunction of doxorubicin-induced cardiotoxicity.
In Chapter 5 authors deal with cardiotoxicity related to doxorubicin therapy. The mechanisms underlying cardiotoxicity of doxorubicin are complex. No single drug is able to prevent cardiotoxicity therefore, more clinical studies are needed to elucidate the mechanism and develop strategies in prevention against doxorubicin-induced cardiotoxicity.

Chapter 6 deals with the question of trastuzumab cardiotoxicity in patients with breast cancer Her2+. The use of trastuzumab has changed the natural history of patients with HER-2 positive breast cancer, both in adjuvant and metastatic setting, and has become the standard of care for treatment of these patients. However, the occurrence of symptomatic and asymptomatic cardiac dysfunction is one of major concerns. Several methods are proposed to early identify at-risk patients.
Chapter 7 reviews the issue of critical importance - the detection and prediction of early cardiotoxicity using biomarkers and echocardiographic techniques that can provide the diagnosis of myocardial injury in real time which is one of the main goals for both cardiologists and oncologists.

Manuela Fiuza
Echocardiography Laboratory of the Cardiology
Department of University Hospital Santa Maria,
Lisbon Medical University,



 1 Cardiovascular Pathophysiology Produced by Natural Toxins and Their Possible Therapeutic Implications 1 Robert Frangež, Marjana Grandič and Milka Vrecl

 2 Role of Nitric Oxide in Isoproterenol-Induced Myocardial Infarction 17 Victoria Chagoya de Sánchez, Lucía Yañez-Maldonado, Susana Vidrio-Gómez, Lidia Martínez, Jorge Suárez, Alberto Aranda-Fraustro, Juan Carlos Torres and Gabriela Velasco-Loyden

 3 Cardiac Complications of Cancer Treatment 33 Beata Mlot and Piotr Rzepecki

 4 Neuregulin1-ErbB Signaling in Doxorubicin-Induced Cardiotoxicity 65 David Goukassian, James P. Morgan and Xinhua Yan

 5 Doxorubicin-Induced Oxidative Injury of Cardiomyocytes – Do We Have Right Strategies for Prevention? 89 Vukosava Milic Torres and Viktorija Dragojevic Simic

 6 Trastuzumab and Cardiotoxicity 131 M. Fiuza and A. Magalhães

 7 Early Detection and Prediction of Cardiotoxicity – Biomarker and Echocardiographic Evaluation 153 Elena Kinova and Assen Goudev

You've just read an article category Cardiology and Cardiovascular / Oncology and Hematology / Pharmacology and Toxicology by title TEXTBOOK : CARDIOTOXICITY OF ONCOLOGIC TREATMENTS. You can bookmark this page URL Thank you!
Published by: Unknown - Monday, May 13, 2013


Post a Comment